Non-Hodgkin's Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Conditions: Non-hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); High-grade B-cell Lymphoma; Grade 3b F ollicular Lymphoma; Mantle Cell Lymphoma Interventions: Drug: CD79b-19 CAR T cells; Drug: Cyclophosphamide; Drug: Fludarabine Sponsor: Marcela V. Maus, M.D.,Ph.D. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Conditions: B-Cell Non Hodgkin Lymphoma; B-Cell Acute Lymphoblastic Leukemia Intervention: Biological: anti-CD19 CAR T-cells Sponsors: Vinmec Research Institute of Stem Cell and Gene Technology; National Institute of Hematology and Blood Transfusion, Vietnam Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Condition: CD20-positive Non-Hodgkin Lymphoma Intervention: Drug: EX103 injection Sponsor: Guangzhou Excelmab Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials